Loading
A phase 2/3 trial testing NB003 in gastrointestinal stromal tumour, now recruiting.
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST) is a phase 2/3 interventional study registered as NCT07379047, led by Ningbo Newbay Technology Development, and recruiting on the registry. Official title: A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST). Planned enrolment is 255 participants (estimated). The study started in 2026-05-11 and primary completion is expected in 2028-08-01. No results have been posted on ClinicalTrials.gov.